Studies Open for Enrollment

Study Name	*Indication*	*Principal Investigator*	*For more information visit*
Heart Hospital Office			
ALLSTAR Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients with a Myocardial Infarction and Ischemic Left Ventricular Dysfunction	Adult stem cells - Post MI/LV dysfunction	Roger Gammon, MD	https://clinicaltrials.gov/ct2/show/NCT02032004
AMAZE Left Atrial Appendage Ligation with the LARIAT Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation for Persistent or Longstanding Persistent Atrial Fibrillation	LARIAT ligation of Left Atrial Appendage for chronic Afib	David Tschopp, MD	https://clinicaltrials.gov/ct2/show/NCT02513797
CardioMEMS CardioMEMS HF System Post Approval Study	Patients with class III heart failure	Kunjan Bhatt, MD	https://clinicaltrials.gov/ct2/show/NCT2279888
CardioMEMS CRT Evaluation of Acute Changes Observed with CardioMEMS During	Patients already implanted with both a	Kunjan Bhatt, MD	N/A

Quadripolar CRT Programming Testing	CardioMEMS device and a SJM Quadripolar Pacing System		
CONVERGE Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF	RF ablation for persistant AFib	David Tschopp, MD	https://clinicaltrials.gov/ct2/show/NCT01984346
Dal-GenE A phase III, double blind, randomized placebo--controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in a genetically defined population with a recent Acute Coronary Syndrome	Pts. With recent ACS with AA genotype to reduce CV events	Mark Picone, DO	https://clinicaltrials.gov/ct2/show/NCT02525939
DREAM-HF A Double-Blind, Randomized, Sham-Procedure-Controlled, Parallel-Group Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (CEP-41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology	Allogeneic Mesenchymal Cells for patients with chronic heart failure	Roger Gammon, MD	https://clinicaltrials.gov/ct2/show/NCT02032004
EVOLVE Short-DAPT A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet	3 month DAPT for pts. at high risk for bleeding that received the	Craig Siegel, MD	https://clinicaltrials.gov/ct2/show/NCT02605447

Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System	Synergy stent		
Lutonix-BTK A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries	Drug Eluting Stent for BTK Peripheral Artery Disease	Roger Gammon, MD	https://clinicaltrials.gov/ct2/show/NCT01870401
MIMICS-2 The Evaluation of Safety and Efficacy of the BioMimics 3D Nitinol Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Artery Disease	Stent System for SFA/Pop lesions	Roger Gammon, MD	https://clinicaltrials.gov/ct2/show/NCT02400905
PARTNER 3 A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific, Symptomatic Aortic Stenosis	Severe calcific aortic stenosis requiring aortic valve replacement for low risk patients TAVR vs. SAVR	Frank Zidar, MD & Faraz Kerendi, MD	https://clinicaltrials.gov/ct2/show/NCT02675114

PARTNER S3i CAP The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve with Associated Delivery Systems in Intermediate Patients with Severe Symptomatic Aortic Stenosis	TAVR in moderate risk patients	Frank Zidar, MD & Faraz Kerendi, MD	https://clinicaltrials.gov/ct2/show/NCT02687035
SALUS The Direct Flow Medical Transcatheter Aortic Valve Replacement System Pivotal Trial.	Symptomatic patients with severe aortic valve stenosis who require replacement of their native aortic valve, who are extreme or high risk	Juhana Karha, MD & Steven Dewan, MD	https://clinicaltrials.gov/ct2/show/NCT02163850
SPIRE Phase 3 multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of bococizumab (pf-04950615), in reducing the occurrence of major cardiovascular events in high risk subjects	Bococizumab vs placebo in patients with high cholesterol not controlled with statins	Roger Gammon, MD	https://clinicaltrials.gov/ct2/show/NCT01975376
San Marcos Office			
CardioMEMS CardioMEMS HF System Post	Patients with class III heart failure	Kunjan Bhatt, MD	https://clinicaltrials.gov/ct2/show/NCT2279888

Approval Study			
EVOLVE Short-DAPT A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System	3 month DAPT for pts. at high risk for bleeding that received the Synergy stent	Craig Siegel, MD	https://clinicaltrials.gov/ct2/show/NCT02605447
Round Rock Office			
EVOLVE Short-DAPT A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System	3 month DAPT for pts. at high risk for bleeding that received the Synergy stent	Craig Siegel, MD	https://clinicaltrials.gov/ct2/show/NCT02605447
Harker Heights Office			
Currently no active enrolling studies			